VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

VERTEX PHARMACEUTICALS INC / MA

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$501.95+2.21 (+0.44%)

Close on Oct 19, 2026

Community

Notes and questions about Vertex Pharmaceuticals Inc / Ma from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Vertex Pharmaceuticals Inc / Ma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Aug 24, 2000
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRTX.

Revenue growth10.2% · median 6.8%

Gross margin86.0% · median 64.4%

Operating margin38.0% · median 16.1%

Net margin35.0% · median 15.3%

Advertisement
300 × 250